Over the past twelve months, Esperion has evolved from a single bempedoic acid franchise story to a more articulated commercial-stage biotech case with three concurrent drivers: U.S. commercial growth, international partner monetization, and portfolio expansion through the acquisition of Corstasis Therapeutics. The company leverages deep expertise in ACLY biology, a critical metabolic enzyme positioned at the intersection of nutrient catabolism and cholesterol and fatty acid biosynthesis.
Cyborg Score Rationale
Esperion reported Q1 2026 revenue of $80.1 million, up from $65.0 million a year earlier, with a narrower net loss of $25.2 million versus $40.5 million. Full-year 2025 closed with total revenue of $403.1 million, up 21% year-over-year, with U.S. net product revenue at $159.6 million, up 38%. However, analyst sentiment remains cautious with "Hold" ratings prevailing.
Top Insights
Esperion achieved 2025 total revenue of $403.1 million (up 21% YoY), with U.S. net product revenue reaching $159.6 million (up 38%), demonstrating acceleration in core commercial execution and pricing power.
Esperion completed the acquisition of Corstasis in April 2026 and is preparing to launch Enbumyst for heart failure, significantly expanding its cardiovascular franchise and diversifying beyond bempedoic acid monotherapy.
In February 2026, Esperion secured a landmark generic blocking agreement with Alkem Laboratories, preventing competing generics of NEXLETOL and NEXLIZET in the U.S. market until April 2040, extending franchise runway.
Named Competitors
LEQVIO (inclisiran) — PCSK9-inhibiting siRNA therapy for LDL-C reduction in cardiovascular disease
Repatha (evolocumab) — PCSK9 inhibitor monoclonal antibody for cholesterol management
Praluent (alirocumab) — PCSK9 inhibitor for elevated LDL-C in high-risk cardiovascular patients
Nexletol (bempedoic acid) — ACLY inhibitor oral non-statin for LDL-C reduction in cardiovascular disease
Recent Developments
(April 2026) Completed acquisition of Corstasis Therapeutics for product Enbumyst (bumetanide nasal spray) for heart failure
(February 2026) Secured generic blocking agreement with Alkem Laboratories through April 2040 for NEXLETOL and NEXLIZET
(January 2026) Announced Vision 2040 Growth Strategy targeting global expansion and multi-product sustainable platform
Open the full interactive Esperion Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.